COVID-19 vaccine effectiveness
(Randomized evidence)
If you want to see all comparisons, please click here
Sinopharm-Beijng-HB02 COVID-19 Vaccine vs Placebo
You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.
Forest plots
(last update: 2021-06-04)
Summary of findings
2021-06-11
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04510207, ChiCTR2000034780 Sinopharm - China National Biotec Group Company Limited Al Kaabi N, JAMA, 2021 Full text Commentary Commentary |
Inactivated virus |
WIV04 HBO2 |
Placebo |
RCTPhase 3 | Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain | N=40411 |
Some concerns Details |
|
|
ChiCTR2000032459 Beijing Institute of Biological Products/Sinopharm Xia S, Lancet Infect Dis, 2020 Full text Commentary |
Inactivated virus |
BBIBP-CorV 8mcg once BBIBP-CorV 4mcg D0/14 BBIBP-CorV 4mcg D0/21 BBIBP-CorV 4mcg D0/28 |
Placebo |
RCTPhase 2 | Healthy SARS-CoV-2 serology negative adults 18-59 years old and ≥60 years old in a single centre in China | N=448 |
Some concerns Details |
|